Canadian adaptive platform trial of treatments for COVID in community settings (CanTreatCOVID): recruitment strategies of a decentralized, national randomized controlled trial for acute SARS-CoV-2

加拿大针对社区环境中 COVID-19 治疗的适应性平台试验 (CanTreatCOVID):一项针对急性 SARS-CoV-2 的分散式全国随机对照试验的招募策略

阅读:2

Abstract

BACKGROUND: Recruitment remains a challenge in clinical trials. This study describes the use of digital and traditional recruitment channels in a national, community-based adaptive platform trial for COVID-19 in Canada. METHODS: Self-reported recruitment sources were collected from participants of a remote, national adaptive platform trial of COVID-19 treatments conducted across six Canadian provinces using a secure web-based application. Recruitment channels were analyzed using descriptive statistics, chi-square tests, and logistic regression to explore associations with province. RESULTS: From January 2023 to September 2024, 1,515 participants completed the pre-screening process, and 720 were randomized. Of them, 416 were recruited through traditional channels, 303 through digital channels, and one through an undetermined source. Recruitment channels varied by province (χ (2)(5) = 81.30, p < 0.001; Cramér's V = 0.34), and digital channels were associated with higher odds of recruitment compared with traditional channels (adjusted OR = 2.78, 95% CI 2.20-3.52). The most frequently reported referral source was 'family, friends, or colleagues' (20%), followed by provincial government websites and health lines (16.25%), online channels (10.56%), and public communications (9.86%). CONCLUSION: Combining traditional and digital recruitment methods supports recruitment. Trials can raise awareness of the study by leveraging both digital and traditional channels and can move information to action through trusted social groups and institutions. Further research is needed to evaluate the cost-effectiveness, reach, and demographic differences across platforms, informing recruitment strategies in future decentralized and adaptive trials beyond COVID-19. CLINICAL TRIAL REGISTRATION: https://clinicaltrials.gov/study/NCT05614349, Identifier NCT05614349.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。